EP3082817A4 - Compositions pour administration de médicaments - Google Patents
Compositions pour administration de médicaments Download PDFInfo
- Publication number
- EP3082817A4 EP3082817A4 EP14872645.8A EP14872645A EP3082817A4 EP 3082817 A4 EP3082817 A4 EP 3082817A4 EP 14872645 A EP14872645 A EP 14872645A EP 3082817 A4 EP3082817 A4 EP 3082817A4
- Authority
- EP
- European Patent Office
- Prior art keywords
- compositions
- drug administration
- administration
- drug
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/485—Morphinan derivatives, e.g. morphine, codeine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4535—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/26—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0043—Nose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US14/133,350 US9895444B2 (en) | 2004-08-25 | 2013-12-18 | Compositions for drug administration |
PCT/US2014/070944 WO2015095389A1 (fr) | 2013-12-18 | 2014-12-17 | Compositions pour administration de médicaments |
Publications (2)
Publication Number | Publication Date |
---|---|
EP3082817A1 EP3082817A1 (fr) | 2016-10-26 |
EP3082817A4 true EP3082817A4 (fr) | 2017-06-21 |
Family
ID=53403653
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP14872645.8A Withdrawn EP3082817A4 (fr) | 2013-12-18 | 2014-12-17 | Compositions pour administration de médicaments |
Country Status (2)
Country | Link |
---|---|
EP (1) | EP3082817A4 (fr) |
WO (1) | WO2015095389A1 (fr) |
Families Citing this family (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9895444B2 (en) | 2004-08-25 | 2018-02-20 | Aegis Therapeutics, Llc | Compositions for drug administration |
BR112014016889A8 (pt) | 2012-01-09 | 2017-07-04 | Adocia | composição sob a forma de uma solução aquosa injetável, sujo ph está compreendido entre 6,0 e 8,0 e, formulação de dose unitária com ph compreendido entre 7 e 7,8 |
US20150314003A2 (en) | 2012-08-09 | 2015-11-05 | Adocia | Injectable solution at ph 7 comprising at least one basal insulin the isoelectric point of which is between 5.8 and 8.5 and a hydrophobized anionic polymer |
BR112018075259A2 (pt) | 2016-06-07 | 2019-03-12 | Adocia | composição na forma de uma solução aquosa injetável, cujo ph é de 6,0 a 8,0 |
CN110139651A (zh) * | 2016-11-18 | 2019-08-16 | 欧邦特制药公司 | 用于治疗阿片样物质过量的组合物和方法 |
WO2019110837A1 (fr) | 2017-12-07 | 2019-06-13 | Adocia | Compositions sous forme d'une solution aqueuse injectable comprenant du glucagon humain et un co-polyaminoacide |
BR112020011484A2 (pt) | 2017-12-07 | 2020-11-17 | Adocia | composições na forma de uma solução aquática injetável compreendendo glucagon humano e um co-poliaminoácido |
FR3083087A1 (fr) | 2018-06-29 | 2020-01-03 | Adocia | Compositions sous forme d'une solution aqueuse injectable comprenant du glucagon humain et un co-polyaminoacide |
CN111683675A (zh) | 2017-12-07 | 2020-09-18 | 阿道恰公司 | 包含人胰高血糖素和共聚氨基酸的呈可注射水溶液形式的组合物 |
US20190275110A1 (en) | 2017-12-07 | 2019-09-12 | Adocia | Compositions in the form of an injectale aqueous solution comprising human glucagon and a co-polyamino acid |
CN110505873B (zh) * | 2018-02-06 | 2022-12-30 | 爱奇司治疗公司 | 鼻内肾上腺素制剂及治疗疾病的方法 |
JP6941224B2 (ja) | 2018-02-06 | 2021-09-29 | イージス セラピューティクス,エルエルシー | 疾患の処置のための鼻腔内エピネフリン製剤及び方法 |
WO2019182745A1 (fr) | 2018-03-19 | 2019-09-26 | Bryn Pharma, LLC | Formulations pour la pulvérisation d'épinéphrine |
FR3067247A1 (fr) | 2018-06-07 | 2018-12-14 | Adocia | Compositions sous forme d'une solution aqueuse injectable comprenant du glucagon humain et un co-polyaminoacide |
US10653690B1 (en) | 2019-07-09 | 2020-05-19 | Orexo Ab | Pharmaceutical composition for nasal delivery |
US10729687B1 (en) * | 2019-07-09 | 2020-08-04 | Orexo Ab | Pharmaceutical composition for nasal delivery |
EP3962455B1 (fr) | 2020-05-18 | 2022-08-31 | Orexo AB | Nouvelle composition pharmaceutique pour une administration de médicament |
EP4236921A1 (fr) | 2021-11-25 | 2023-09-06 | Orexo AB | Composition pharmaceutique comprenant de l'adrénaline |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2000076506A1 (fr) * | 1999-06-16 | 2000-12-21 | Nastech Pharmaceutical Co., Inc. | Formulations pharmaceutiques et procedes comprenant de la morphine s'administrant par voie intra-nasale |
WO2004054542A2 (fr) * | 2002-12-13 | 2004-07-01 | Durect Corporation | Systeme d'administration de medicaments par voie orale |
US20060045868A1 (en) * | 2004-08-25 | 2006-03-02 | Aegis Therapeutics Llc | Absorption enhancers for drug administration |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6608073B1 (en) * | 1998-10-14 | 2003-08-19 | New Millennium Pharmaceutical Research, Inc. | Intranasal codeine for the rapid suppression of cough and rapid relief of pain |
US8440631B2 (en) * | 2008-12-22 | 2013-05-14 | Aegis Therapeutics, Llc | Compositions for drug administration |
WO2013032934A1 (fr) * | 2011-08-26 | 2013-03-07 | Aegis Therapeutics, Llc | Compositions et leurs procédés pour une administration orale de médicaments |
-
2014
- 2014-12-17 WO PCT/US2014/070944 patent/WO2015095389A1/fr active Application Filing
- 2014-12-17 EP EP14872645.8A patent/EP3082817A4/fr not_active Withdrawn
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2000076506A1 (fr) * | 1999-06-16 | 2000-12-21 | Nastech Pharmaceutical Co., Inc. | Formulations pharmaceutiques et procedes comprenant de la morphine s'administrant par voie intra-nasale |
WO2004054542A2 (fr) * | 2002-12-13 | 2004-07-01 | Durect Corporation | Systeme d'administration de medicaments par voie orale |
US20060045868A1 (en) * | 2004-08-25 | 2006-03-02 | Aegis Therapeutics Llc | Absorption enhancers for drug administration |
Non-Patent Citations (4)
Title |
---|
DAVIS S S ET AL: "ABSORPTION ENHANCERS FOR NASAL DRUG DELIVERY", CLINICAL PHARMACOKINETICS, ADIS INTERNATIONAL LTD., AUCKLAND, NZ, vol. 42, no. 13, 1 January 2003 (2003-01-01), pages 1107 - 1128, XP009040612, ISSN: 0312-5963, DOI: 10.2165/00003088-200342130-00003 * |
EDWARD T MAGGIO: "Intravail: highly effective intranasal delivery of peptide and protein drugs", EXPERT OPINION ON DRUG DELIVERY, INFORMA HEALTHCARE, GB, vol. 3, no. 4, 1 July 2006 (2006-07-01), pages 529 - 539, XP008152448, ISSN: 1742-5247, DOI: 10.1517/17425247.3.4.529 * |
EDWARD T. MAGGIO ET AL: "High efficiency intranasal drug delivery using Intravail alkylsaccharide absorption enhancers", DRUG DELIVERY AND TRANSLATIONAL RESEARCH, vol. 3, no. 1, 12 May 2012 (2012-05-12), Germany, pages 16 - 25, XP055370902, ISSN: 2190-393X, DOI: 10.1007/s13346-012-0069-z * |
See also references of WO2015095389A1 * |
Also Published As
Publication number | Publication date |
---|---|
WO2015095389A1 (fr) | 2015-06-25 |
EP3082817A1 (fr) | 2016-10-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL288961A (en) | Pharmaceutical preparations | |
EP3082817A4 (fr) | Compositions pour administration de médicaments | |
EP3089736A4 (fr) | Compositions pharmaceutiques pour composés faiblement hydrosolubles | |
PL2943181T3 (pl) | Kompozycje farmaceutyczne | |
EP4005604B8 (fr) | Administration de médicaments | |
EP3077006A4 (fr) | Conjugués polymères-hydrates de carbone pour technologie d'administration pharmacologique | |
HK1212899A1 (zh) | 包含癌莫事 之醫藥組合物 | |
ZA201401683B (en) | Pharmaceutical compositions for rectal administration | |
ZA201408333B (en) | Pharmaceutical compositions | |
EP2990039A4 (fr) | Composition pharmaceutique solide | |
EP3087987A4 (fr) | Composition pharmaceutique contenant du palonosétron | |
EP3003324A4 (fr) | Compositions pharmaceutiques | |
HK1231390A1 (zh) | 用於局部給藥的藥用組合物 | |
EP3020417A4 (fr) | Composition pharmaceutique à administrer par les voies respiratoires | |
TWI800759B (zh) | 醫藥劑型 | |
EP3043648A4 (fr) | Compositions pharmaceutiques de bendamustine | |
EP3041478A4 (fr) | Compositions de vaccin pour toxicomanie | |
EP3003369A4 (fr) | Compositions pharmaceutiques comprenant un pyrophosphate | |
HRP20171888T1 (hr) | Farmaceutski pripravci | |
HUP1300496A2 (hu) | Stabil kombinációs gyógyszerkészítmény | |
EP3065746A4 (fr) | Compositions thérapeutiques | |
EP3006033A4 (fr) | Médicament anticancéreux | |
EP3082783A4 (fr) | Composition pharmaceutique orale stable | |
EP2992890A4 (fr) | Composition pharmaceutique | |
EP2979698A4 (fr) | Composition pharmaceutique pour administration orale |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20160614 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
AX | Request for extension of the european patent |
Extension state: BA ME |
|
DAX | Request for extension of the european patent (deleted) | ||
A4 | Supplementary search report drawn up and despatched |
Effective date: 20170522 |
|
RIC1 | Information provided on ipc code assigned before grant |
Ipc: A61P 25/04 20060101ALI20170516BHEP Ipc: A61K 47/26 20060101ALI20170516BHEP Ipc: A61K 31/485 20060101AFI20170516BHEP Ipc: A61K 9/00 20060101ALI20170516BHEP |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: EXAMINATION IS IN PROGRESS |
|
17Q | First examination report despatched |
Effective date: 20191008 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: EXAMINATION IS IN PROGRESS |
|
RAP3 | Party data changed (applicant data changed or rights of an application transferred) |
Owner name: AEGIS THERAPEUTICS, LLC |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION HAS BEEN WITHDRAWN |
|
18W | Application withdrawn |
Effective date: 20211201 |